

September 1, 2005

Choseido Pharmaceutical Co., Ltd.
Astellas Pharma Inc.

Transfer of *Almatol*[®] tablets and *Helmitin*[®] S suppositories to Choseido

Japan, September 1, 2005 - Choseido Pharmaceutical Co., Ltd. (Head Office: Tokushima, President: Hisaaki Harima, hereafter referred as “Choseido”) and Astellas Pharma Inc. (Head Office: Tokyo, President & CEO: Toichi Takenaka, hereafter referred as “Astellas”) announced today that Astellas and Choseido have agreed on the transfer of marketing and manufacturing rights for potassium-sparing diuretic aldosterone antagonist *Almatol*[®] tablets (generic name: spironolactone) and *Helmitin*[®] S suppositories (generic name: lidocaine, ethyl aminobenzoate, bismuth subgallate) for the treatment of hemorrhoids and perianal pain of Astellas to Choseido effective October 1, 2005.

Choseido will start product distribution as well as information provision and gathering on the drugs at medical institutions in Japan from October 1, 2005.

#####

Contacts for further or additional information
Choseido Pharmaceutical Co., Ltd. Mr. Hideaki Harada, Manufacturing Dept. Tel:+81-88-642-1101 Fax:+81-88-642-3337 http://www.choseido.com/ (Japanese only)
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com